Suppression of premature termination codons as a therapeutic approach

  • Keeling K
  • Wang D
  • Conard S
 et al. 
  • 65

    Readers

    Mendeley users who have this article in their library.
  • 46

    Citations

    Citations of this article.

Abstract

In this review, we describe our current understanding of translation termination and pharmacological agents that influence the accuracy of this process. A number of drugs have been identified that induce suppression of translation termination at in-frame premature termination codons (PTCs; also known as nonsense mutations) in mammalian cells. We discuss efforts to utilize these drugs to suppress disease-causing PTCs that result in the loss of protein expression and function. In-frame PTCs represent a genotypic subset of mutations that make up ~11% of all known mutations that cause genetic diseases, and millions of patients have diseases attributable to PTCs. Current approaches aimed at reducing the efficiency of translation termination at PTCs (referred to as PTC suppression therapy) have the goal of alleviating the phenotypic consequences of a wide range of genetic diseases. Suppression therapy is currently in clinical trials for treatment of several genetic diseases caused by PTCs, and preliminary results suggest that some patients have shown clinical improvements. While current progress is promising, we discuss various approaches that may further enhance the efficiency of this novel therapeutic approach.

Author-supplied keywords

  • Nonsense mutations
  • Premature termination codons
  • Suppression therapy
  • Translation termination

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Kim M. Keeling

  • Dan Wang

  • Sara E. Conard

  • David M. Bedwell

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free